2019
Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension
Abraldes JG, Trebicka J, Chalasani N, D’Amico G, Rockey DC, Shah VH, Bosch J, Garcia‐Tsao G. Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension. Hepatology 2019, 69: 1287-1299. PMID: 30318607, PMCID: PMC11090176, DOI: 10.1002/hep.30314.Peer-Reviewed Original ResearchConceptsNonalcoholic fatty liver diseasePortal pressurePortal hypertensionLiver diseaseCardiac output leadsCause of cirrhosisCirrhotic portal hypertensionChronic liver diseaseFatty liver diseasePortal venous inflowIntrahepatic vascular resistanceRisk of decompensationEarly clinical studiesCirrhosis decompensationSplanchnic vasodilationVascular resistancePharmacological therapyEtiological treatmentVenous inflowCirrhosis resultsSuch therapyClinical trialsBest therapyClinical studiesCirrhosis
1994
A Comparative Clinical Study of Idiopathic Portal Hypertension, Extrahepatic Portal Vein Thrombosis, and Cirrhosis
Orozco H, Takahashi T, Garcia-Tsao G, Mercado M, Prado E, Nava R. A Comparative Clinical Study of Idiopathic Portal Hypertension, Extrahepatic Portal Vein Thrombosis, and Cirrhosis. Journal Of Clinical Gastroenterology 1994, 19: 217-221. PMID: 7806833, DOI: 10.1097/00004836-199410000-00010.Peer-Reviewed Original ResearchConceptsExtrahepatic portal vein thrombosisIdiopathic portal hypertensionPortal vein thrombosisLiver cirrhosisPortal hypertensionVein thrombosisClinical featuresLC patientsComparative clinical studySeparate clinical entityLiver failureLaboratory variablesClinical entityRetrospective studyClinical studiesPatientsStatistical differenceHypertensionCirrhosisThrombosisHigher proportionSurvivalSimilar distributionGroup